73 related articles for article (PubMed ID: 15018324)
1. Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
Jito J; Nakasu Y; Nakasu S; Hatsuda N; Matsuda M
Neurol Med Chir (Tokyo); 2004 Feb; 44(2):55-60; discussion 60. PubMed ID: 15018324
[TBL] [Abstract][Full Text] [Related]
2. Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysis using tissue-type plasminogen activator combined with continuous cisternal drainage.
Kinouchi H; Ogasawara K; Shimizu H; Mizoi K; Yoshimoto T
Neurol Med Chir (Tokyo); 2004 Nov; 44(11):569-75; discussion 576-7. PubMed ID: 15686175
[TBL] [Abstract][Full Text] [Related]
3. Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Usui M; Saito N; Hoya K; Todo T
Neurosurgery; 1994 Feb; 34(2):235-44; discussion 244-5. PubMed ID: 8177383
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain.
Kramer AH; Jenne C; Holodinsky JK; Todd S; Roberts DJ; Kubes P; Zygun DA; Hill MD; Leger C; Wong JH
Neurocrit Care; 2015 Dec; 23(3):386-93. PubMed ID: 25739904
[TBL] [Abstract][Full Text] [Related]
5. Experimental study of intracisternal administration of tissue-type plasminogen activator followed by cerebrospinal fluid drainage in the ultra-early stage of subarachnoid haemorrhage.
Kawada S; Kinugasa K; Meguro T; Hirotsune N; Tokunaga K; Kamata I; Nakashima H; Ohmoto T
Acta Neurochir (Wien); 1999; 141(12):1331-8. PubMed ID: 10672305
[TBL] [Abstract][Full Text] [Related]
6. Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
Mizoi K; Yoshimoto T; Takahashi A; Fujiwara S; Koshu K; Sugawara T
J Neurosurg; 1993 Mar; 78(3):430-7. PubMed ID: 8433145
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Zabramski JM; Spetzler RF; Lee KS; Papadopoulos SM; Bovill E; Zimmerman RS; Bederson JB
J Neurosurg; 1991 Aug; 75(2):189-96. PubMed ID: 1906534
[TBL] [Abstract][Full Text] [Related]
8. Early treatment of subarachnoid hemorrhage after preventing rerupture of an aneurysm.
Kinugasa K; Kamata I; Hirotsune N; Tokunaga K; Sugiu K; Handa A; Nakashima H; Ohmoto T; Mandai S; Matsumoto Y
J Neurosurg; 1995 Jul; 83(1):34-41. PubMed ID: 7782847
[TBL] [Abstract][Full Text] [Related]
9. Failure of intracisternal tissue plasminogen activator to prevent vasospasm in certain patients with aneurysmal subarachnoid hemorrhage.
Steinberg GK; Vanefsky MA; Marks MP; Adler JR; Koenig GH
Neurosurgery; 1994 May; 34(5):809-13; discussion 813-4. PubMed ID: 8052377
[TBL] [Abstract][Full Text] [Related]
10. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage.
Ikeda K; Asakura H; Futami K; Yamashita J
Neurosurgery; 1997 Aug; 41(2):344-9; discussion 349-50. PubMed ID: 9257301
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Seifert V; Eisert WG; Stolke D; Goetz C
Neurosurgery; 1989 Oct; 25(4):590-8. PubMed ID: 2507953
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus.
Whitelaw A; Saliba E; Fellman V; Mowinckel MC; Acolet D; Marlow N
Arch Dis Child Fetal Neonatal Ed; 1996 Jul; 75(1):F20-6. PubMed ID: 8795351
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage.
Yamamoto T; Esaki T; Nakao Y; Mori K
World Neurosurg; 2010 Jun; 73(6):675-82. PubMed ID: 20934155
[TBL] [Abstract][Full Text] [Related]
14. Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage.
Findlay JM; Weir BK; Kassell NF; Disney LB; Grace MG
J Neurosurg; 1991 Aug; 75(2):181-8. PubMed ID: 1906533
[TBL] [Abstract][Full Text] [Related]
15. Use of intraventricular tissue plasminogen activator and Guglielmi detachable coiling for the acute treatment of casted ventricles from cerebral aneurysm hemorrhage: two technical case reports.
Azmi-Ghadimi H; Heary RF; Farkas JE; Hunt CD
Neurosurgery; 2002 Feb; 50(2):421-4; discussion 424-5. PubMed ID: 11844282
[TBL] [Abstract][Full Text] [Related]
16. Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator.
Varelas PN; Rickert KL; Cusick J; Hacein-Bey L; Sinson G; Torbey M; Spanaki M; Gennarelli TA
Neurosurgery; 2005 Feb; 56(2):205-13; discussion 205-13. PubMed ID: 15670368
[TBL] [Abstract][Full Text] [Related]
17. Combined cisternal drainage and intrathecal urokinase injection therapy for prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Moriyama E; Matsumoto Y; Meguro T; Kawada S; Mandai S; Gohda Y; Sakurai M
Neurol Med Chir (Tokyo); 1995 Oct; 35(10):732-6. PubMed ID: 8532128
[TBL] [Abstract][Full Text] [Related]
18. Intracisternal administration of tissue plasminogen activator improves cerebrospinal fluid flow and cortical perfusion after subarachnoid hemorrhage in mice.
Siler DA; Gonzalez JA; Wang RK; Cetas JS; Alkayed NJ
Transl Stroke Res; 2014 Apr; 5(2):227-37. PubMed ID: 24526376
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
20. Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurysmal subarachnoid hemorrhage.
Ramakrishna R; Sekhar LN; Ramanathan D; Temkin N; Hallam D; Ghodke BV; Kim LJ
Neurosurgery; 2010 Jul; 67(1):110-7; discussion 117. PubMed ID: 20559098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
